The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy. NCX 470 is Nicox’s lead dual-mechanism bimatoprost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback